"Vaginal progesterone to prevent spontaneous preterm birth in women wit" by Roberto Romero, Arun Meyyazhagan et al.
 

Vaginal progesterone to prevent spontaneous preterm birth in women with a sonographic short cervix: The story of the PREGNANT trial

Document Type

Article (peer-reviewed)

Publication Date

6-1-2024

Abstract

The PREGNANT trial was a randomized, placebo-controlled, multicenter trial designed to determine the efficacy and safety of vaginal progesterone (VP) to reduce the risk of birth < 33 weeks and of neonatal complications in women with a sonographic short cervix (10 to 20 mm) in the mid-trimester (19 to 23 6/7 wk). Patients allocated to receive VP had a 45% lower rate of preterm birth (8.9% vs 16.1%; relative risk = 0.55; 95% CI: 0.33-0.92). Neonates born to mothers allocated to VP had a 60% reduction in the rate of respiratory distress syndrome. This article reviews the background, design, execution, interpretation, and impact of the PREGNANT Trial.

DOI

10.1097/GRF.0000000000000867

Language

English

https://doi.org/10.1097/GRF.0000000000000867

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 3
  • Usage
    • Abstract Views: 9
  • Captures
    • Readers: 18
see details

Share

COinS